Vault-13

TEVA PHARMACEUTICAL-SP ADR TEVA

ADR · Common Stock · CUSIP M8769Q102

Israeli pharmaceutical company

0 institutional holders -1 vs Q3 2025
—reported value*
0 new 0 added 0 reduced 1 sold out net sold ≈ $637.6k (-31.6k shares)

* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable.

Trends to Q4 2025

Institutional holders

Managers reporting a position, each quarter

001Q2 25: 1Q3 25: 1Q4 25: 00Q2 25Q3 25Q4 25
Numbers
QuarterHolders
Q2 20251
Q3 20251
Q4 20250

Buyers vs sellers

Managers adding to or starting a position, vs cutting or selling out

Bought or addedCut or sold out
101Q3 25: 0 bought or addedQ3 25: 1 cut or sold outQ3 25Q4 25: 0 bought or addedQ4 25: 1 cut or sold outQ4 25
Numbers
QuarterBought or addedCut or sold out
Q3 202501
Q4 202501

Biggest buyers

None

Biggest sellers

OLD MISSION CAPITAL LLC Sold out -31,565-31.6k

Major shareholders (over 5%)

Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.

HolderStakeChangeShares Last filed
Harel Insurance Investments & Financial Services Ltd. 13G · passive investor +1.2 pts · filed 2026-02-09 6.3% +1.2 pts 72.3m 2026-02-09

Insider purchases and sales in Q4 2025

Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.

Officers and directors buying vs selling

Number of people, by quarter (10% owners not included)

BuyingSelling
10010Q1 24: 0 buyingQ1 24: 8 sellingQ2 24: 0 buyingQ2 24: 3 sellingQ2 24Q3 24: 0 buyingQ3 24: 3 sellingQ4 24: 0 buyingQ4 24: 2 sellingQ4 24Q1 25: 0 buyingQ1 25: 7 sellingQ2 25: 0 buyingQ2 25: 3 sellingQ2 25Q3 25: 1 buyingQ3 25: 2 sellingQ4 25: 0 buyingQ4 25: 5 sellingQ4 25
Numbers
QuarterBuyingBoughtSellingSoldSold under a plan
Q1 20240—8$9.0m$5.0m
Q2 20240—3$9.6m—
Q3 20240—3$3.0m$493.5k
Q4 20240—2$6.6m$327.1k
Q1 20250—7$11.2m$8.3m
Q2 20250—3$7.2m$952.6k
Q3 20251$21.0k2$891.3k$799.6k
Q4 20250—5$20.1m$699.5k
DateInsiderTradeSharesPrice ValueTheir holding
2025-12-16 MIGNONE ROBERTO Director · [see footnote] Sold 77,400 $30.24 $2.3m77.4k shares -17%
2025-12-16 Weiss Amir Chief Accounting Officer Sold 12,300 $30.20 $371.5k12.3k shares -68%
2025-12-09 Sabag Mark Officer Sold 216,892 $28.73 $6.2m216.9k shares -80%
2025-12-09 Daniell Richard Exec. VP, European Commercial Sold 115,468 $28.68 $3.3m115.5k shares -70%
2025-11-26 MIGNONE ROBERTO Director · [see footnote] Sold 50,000 $26.03 $1.3m50.0k shares -10%
2025-11-20 Fox Christine EVP, Head of U.S. Commercial Sold plan 28,229 $24.78 $699.5k28.2k shares -31%
2025-11-14 Fox Christine EVP, Head of U.S. Commercial Sold 30,000 $25.11 $753.3k30.0k shares -51%
2025-11-06 MIGNONE ROBERTO Director · [see footnote] Sold 200,000 $24.11 $4.8m200.0k shares -29%
2025-11-06 Weiss Amir Chief Accounting Officer Sold 12,300 $24.44 $300.6k12.3k shares -41%

Their holding: how much the trade added to or took from the insider's holding (direct, or the trust or fund named). The same trade is sometimes reported by more than one insider, such as a fund and the director who represents it; totals count it once. A value is left blank where the reported price is far from the market price (usually a typo).

Holders, Q4 2025

#ManagerLocationShares Value% of their portfolioChangeShares change